問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Tri-Service General Hospital

Division of Thoracic Medicine

Division of Thoracic Medicine

Division of Thoracic Medicine

更新時間：2023-09-19

鄭立廷
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

14Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鄭立廷

List

19Cases

2025-06-09 - 2029-11-26

Active
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab in Adult Participants With COPD With Type 2 Inflammation

  • Condition/Disease

    Pulmonary Disease, Chronic Obstructive

  • Test Drug

    預充填式注射劑

Participate Sites
8Sites

Recruiting8Sites

2025-09-01 - 2035-12-31

Phase III

Active
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    錠劑 皮下注射劑

Participate Sites
6Sites

Recruiting6Sites

2025-03-01 - 2028-03-31

Phase I/II

Active
An open-label, multi-group, phase 1b/2 trial evaluating the safety, efficacy, and optimal dose of Telisotuzumab Adizutecan in combination with a PD-1 immune checkpoint inhibitor in treatment-naïve patients with untreatable genetic mutations in advanced or metastatic non-squamous non-small cell lung cancer (AndroMETa-Lung-536).

  • Condition/Disease

    Non-small cell lung cancer

  • Test Drug

    Telisotuzumab Adizutecan (ABBV-400)

Participate Sites
9Sites

Recruiting9Sites

2025-04-01 - 2033-01-20

Active
A phase 3, multicenter, randomized, open-label trial evaluating trastuzumab deruxtecan plus pembrolizumab versus platinum-based chemotherapy plus pembrolizumab as first-line therapy in participants with locally advanced, unresectable or metastatic HER2 overexpression and PD-L1 TPS <50% non-squamous non-small cell lung cancer (DESTINY-Lung06).

  • Condition/Disease

    The efficacy of T-DXd with pembrolizumab versus platinum-based chemotherapy with pembrolizumab was compared using PFS as assessed by BICR. PFS was defined as the time interval elapsed from the date of randomization to the date of radiographic disease progression or death from any cause. Tumor response was assessed by BICR tumor scans and determined using the Solid Tumor Response Assessment Criteria, version 1.1 (RECIST v1.1).

  • Test Drug

    Trastuzumab Deruxtecan

Participate Sites
9Sites

Recruiting9Sites

2025-04-01 - 2027-12-31

Active
A multicenter, open-label, randomized phase 3 trial evaluating sequential administration of THIO and Cemiplimab (LIBTAYO®) versus single-agent chemotherapy of the trial administrator's choice in advanced/metastatic non-small cell lung cancer (NSCLC).

  • Condition/Disease

    OS (defined as the time elapsed from random assignment to death for any reason)

  • Test Drug

    LIBTAYO THIO

Participate Sites
10Sites

Recruiting10Sites

2024-01-01 - 2030-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-09-01 - 2029-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2024-08-20 - 2035-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2024-05-15 - 2032-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2022-01-01 - 2031-02-27

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB